Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma-Safety and outcomes.
Sameer Farouk SaitNancy A KernanElizabeth KleinBarbara SpitzerCarolyn Fein LevyJonathan D FishOnur YildrimSofia HaqueMaria DonzelliMauricio Rendon BernotDavid H AbramsonJasmine H FrancisYasmin KhakooMatthias A KarajannisStephen A SandsNeeta Pandit-TaskarSuzanne L WoldenKim KramerIra J DunkelPublished in: Pediatric blood & cancer (2024)
CSI (23.4 Gy) alone or in conjunction with intraventricular RIT may have clinical utility in eliminating persistent MRD post HDC-ASCT, contributing to improved disease-free survival in patients with CNS RB. This treatment strategy merits evaluation in a prospective, multicenter clinical trial for patients with CNS metastatic RB.
Keyphrases
- free survival
- high dose
- stem cells
- blood brain barrier
- clinical trial
- squamous cell carcinoma
- small cell lung cancer
- low dose
- double blind
- cell therapy
- bone marrow
- locally advanced
- stem cell transplantation
- open label
- type diabetes
- study protocol
- randomized controlled trial
- phase ii
- metabolic syndrome
- radiation induced
- combination therapy
- skeletal muscle
- platelet rich plasma
- phase iii